Cargando…

Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease

OBJECTIVE: To evaluate the cardiovascular and renal benefits of finerenone, sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagonlike peptide-1 receptor agonists (GLP-1 RA) in patients with Type 2 Diabetes Mellitus (T2DM) and chronic kidney disease (CKD) with network meta-analysis. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yaofu, Jiang, Li, Wang, Junheng, Wang, Tongxin, Chien, Chieh, Huang, Weijun, Fu, Xiaozhe, Xiao, Yonghua, Fu, Qiang, Wang, Shidong, Zhao, Jinxi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9637313/ https://www.ncbi.nlm.nih.gov/pubmed/36335326 http://dx.doi.org/10.1186/s12933-022-01676-5

Ejemplares similares

Network meta-analysis on the efficacy and safety of finerenone versus SGLT2 inhibitors on reducing new-onset of atrial fibrillation in patients with type 2 diabetes mellitus and chronic kidney disease
por: Zhang, Yaofu, et al.
Publicado: (2022)

Effect of RG (Coptis root and ginseng) formula in patients with type 2 diabetes mellitus: a study protocol for a randomized controlled and double-blinding trial
por: Jiang, Li, et al.
Publicado: (2022)

Qingre Yiqi Method along with Oral Hypoglycemic Drugs in Treating Adults with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Jiang, Li, et al.
Publicado: (2021)

Comparison the effects of finerenone and SGLT2i on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus: A network meta-analysis
por: Li, Xuefeng, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Complementary actions of finerenone and SGLT2‐i on renal outcomes?: An urgent need for more information
por: Rebelos, Eleni, et al.
Publicado: (2022)

Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis
por: Castellana, Marco, et al.
Publicado: (2019)

Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus
por: Lv, Ruolin, et al.
Publicado: (2023)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

The Efficacy and Safety of the Combination Therapy With GLP-1 Receptor Agonists and SGLT-2 Inhibitors in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
por: Li, Chen, et al.
Publicado: (2022)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Treatment options of traditional Chinese patent medicines for dyslipidemia in patients with prediabetes: A systematic review and network meta-analysis
por: Jiang, Li, et al.
Publicado: (2022)

GLP-1 receptor agonists vs. SGLT-2 inhibitors: the gap seems to be leveling off
por: Giugliano, Dario, et al.
Publicado: (2021)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Call to action: Understanding the differences in the use of SGLT-2 inhibitors and GLP-1 receptor agonists
por: Khedagi, Apurva, et al.
Publicado: (2023)

Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
por: Dadwani, Rahul S., et al.
Publicado: (2023)

Glycemic Variability Impacted by SGLT2 Inhibitors and GLP 1 Agonists in Patients with Diabetes Mellitus: A Systematic Review and Meta-Analysis
por: Lee, Heeyoung, et al.
Publicado: (2021)

Finerenone attenuates myocardial apoptosis, metabolic disturbance and myocardial fibrosis in type 2 diabetes mellitus
por: Jin, Tao, et al.
Publicado: (2023)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER
por: Arnold, Suzanne V., et al.
Publicado: (2022)

Combination Treatment of SGLT2 Inhibitors and GLP-1 Receptor Agonists: Symbiotic Effects on Metabolism and Cardiorenal Risk
por: Goncalves, Edison, et al.
Publicado: (2018)

SGLT2 Inhibitors, GLP-1 Agonists, and DPP-4 Inhibitors in Diabetes and Microvascular Complications: A Review
por: El Mouhayyar, Christopher, et al.
Publicado: (2020)

Inflammation and Oxidative Stress in Diabetic Kidney Disease: The Targets for SGLT2 Inhibitors and GLP-1 Receptor Agonists
por: Winiarska, Agata, et al.
Publicado: (2021)

Evidence for Cardiorenal Protection with SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Patients with Diabetic Kidney Disease
por: Georgianos, Panagiotis I., et al.
Publicado: (2022)

Mini Review: Effect of GLP-1 Receptor Agonists and SGLT-2 Inhibitors on the Growth Hormone/IGF Axis
por: Cignarelli, Angelo, et al.
Publicado: (2022)

Making a case for the combined use of SGLT2 inhibitors and GLP1 receptor agonists for cardiorenal protection
por: Sridhar, Vikas S., et al.
Publicado: (2020)

Characteristics predicting the efficacy of SGLT-2 inhibitors versus GLP-1 receptor agonists on major adverse cardiovascular events in type 2 diabetes mellitus: a meta-analysis study
por: Sohn, Minji, et al.
Publicado: (2023)

SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
por: Patoulias, Dimitrios, et al.
Publicado: (2022)

Commentary: SGLT2is vs. GLP1RAs reduce cardiovascular and all-cause mortality
por: Du, Lixin, et al.
Publicado: (2022)

SGLT2 inhibitors or GLP-1 receptor agonists as second-line therapy in type 2 diabetes: patient selection and perspectives
por: Gurgle, Holly E, et al.
Publicado: (2016)

Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study
por: Baviera, Marta, et al.
Publicado: (2022)

Emerging therapies: The potential roles SGLT2 inhibitors, GLP1 agonists, and ARNI therapy for ARNI pulmonary hypertension
por: King, Nicholas E., et al.
Publicado: (2022)

Systematic review and meta-analysis for prevention of cardiovascular complications using GLP-1 receptor agonists and SGLT-2 inhibitors in obese diabetic patients
por: Uneda, Kazushi, et al.
Publicado: (2021)

Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)
por: Gourdy, Pierre, et al.
Publicado: (2023)

Substantially different findings concerning the cardiovascular and cerebrovascular effectiveness of GLP1RAs vs. SGLT2is
por: Du, Lixin, et al.
Publicado: (2022)

Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis
por: Yamada, Takayuki, et al.
Publicado: (2021)

SGLT2is vs. GLP1RAs Reduce Cardiovascular and All-Cause Mortality
por: Qiu, Mei, et al.
Publicado: (2021)

Network Meta-Analysis on the Effects of SGLT2 Inhibitors Versus Finerenone on Cardiorenal Outcomes in Patients With Type 2 Diabetes and Chronic Kidney Disease
por: Zhao, Li-Min, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Online searches for SGLT-2 inhibitors and GLP-1 receptor agonists correlate with prescription rates in the United States: An infodemiological study
por: Dzaye, Omar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bm2tua2mbkqrkf2rdme1d14pei